Complement 5 targeting small interfering RNA (Argo Biopharma)

N/A

Report date: 2024/03/05 14:42:34
NME

Base Information

Drug NameComplement 5 targeting small interfering RNA (Argo Biopharma)
Drug Alias NameC5 siRNA (Argo Biopharma)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionComplement C5 modulators
TargetsComplement C5
Therapy Area/IndicationsHemoglobinuria, ParoxysmalAtypical Hemolytic Uremic SyndromeGlomerulonephritis, IGA +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Argo Biopharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Argo Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHemoglobinuria, ParoxysmalAtypical Hemolytic Uremic SyndromeGlomerulonephritis, IGA +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A